Oncology Biosimilar Market by Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, and Others), By Drug Type (mAb, Immunomodulators, Hematopoietic Agents, G-CSF, and Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacy, and Online Pharmacy): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024

Description

The report covers forecast and analysis for the oncology biosimilar market on a global and regional level. The study provides historical data from 2015 to 2017 along with a forecast from 2018 to 2024 based revenue (USD Million). The study includes drivers and restraints for the oncology biosimilar market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the oncology biosimilar market on a global level.

In order to give the users of this report a comprehensive view on the oncology biosimilar market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, where test type, drug type, distribution channel and regional segmentation are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new test type launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved on the market on the global and regional basis.

The study provides a decisive view on the oncology biosimilar market by segmenting the market based on test type, drug type, distribution channel, and regions. All the segments have been analyzed based on present and future trends and the market are estimated from 2018 to 2024. 

Based on test type, the oncology biosimilar market is segmented as breast cancer, colorectal cancer, blood cancer, neutropenia cancer, non-small cell lung cancer and others. Based on the distribution channel, the oncology biosimilar market is segmented as retail pharmacies, hospital pharmacy, and online pharmacy. 

Increasing demand for affordable therapies due to the constant increase in cancer patients is one of the major driving factors of oncology biosimilar market. High medical expenses associated with cancer treatment; the lack of awareness and dearth of skilled personnel are factors that influence the market growth during the forecast period.

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further bifurcation into major countries, including the U.S., Canada, Mexico, Germany, Spain, Italy, France, UK, China, Japan, India, and Brazil. This segment includes demand for oncology biosimilar market based on individual segment and test types in all the regions and countries.

The report also includes detailed profiles of end players such as Teva Pharmaceutical Industries Ltd., Biocon, STADA Arzneimittel AG, Sandoz International GmbH, Intas Pharmaceuticals Ltd., Celltrion Inc., Pfizer Inc., Apotex Inc., Dr. Reddy’s Laboratories Ltd., and BIOCAD, among others. 

This report segments the global oncology biosimilar market as follows:

Global Oncology Biosimilar Market: by Test Type

• Breast Cancer
• Colorectal Cancer
• Blood Cancer
• Neutropenia Cancer
• Non-Small Cell Lung Cancer
• Others

Global Oncology Biosimilar Market: Drug Type Segment Analysis:

• mAb
• Immunomodulators
• Hematopoietic Agents
• G-CSF 
• Others

Global Oncology Biosimilar Market: by Distribution Channel

• Retail Pharmacies
• Hospital Pharmacy
• Online Pharmacy

Global Oncology Biosimilar Market: by Region

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• Middle East and Africa

Table Of Content

• Chapter 1. Introduction
  • 1.1. Report description and scope
  • 1.2. Research scope
  • 1.3. Research methodology
    • 1.3.1. Market research process
    • 1.3.2. Market research methodology
•  
• Chapter 2. Executive Summary
  • 2.1. Global Oncology Biosimilar Market, 2015 - 2023 (USD Billion)
  • 2.2. Global Oncology Biosimilar Market: Snapshot
•  
• Chapter 3. Oncology Biosimilar Market Dynamics
  • 3.1. Introduction
  • 3.2. Market drivers
    • 3.2.1. Global Oncology Biosimilar Market drivers: Impact analysis
    • 3.2.2. increasing demand of affordable therapies due to the constant increase in cancer patients worldwide
  • 3.3. Market Restraints
    • 3.3.1. High cost associated with cancer treatment
    • 3.3.2. Dearth of skilled personnel
  • 3.4. Opportunities
    • 3.4.1. Patent Expiry
  • 3.5. Porter's five forces analysis
    • 3.5.1. Bargaining power of suppliers
    • 3.5.2. Bargaining power of buyers
    • 3.5.3. Threat from new entrants
    • 3.5.4. Threat from new substitutes
    • 3.5.5. Degree of competition
  • 3.6. Market attractiveness analysis
    • 3.6.1. Market attractiveness analysis, by Test Type
    • 3.6.2. Market attractiveness analysis, by Drug Type
    • 3.6.3. Market attractiveness analysis, by Distribution Channel
    • 3.6.4. Market attractiveness analysis, by Regional Segment
•  
• Chapter 4. Global Oncology Biosimilar Market - Competitive Landscape
  • 4.1. Company Market Share Analysis
    • 4.1.1. Global Oncology Biosimilar Market: company market share, 2015
  • 4.2. Strategic Development
    • 4.2.1. Acquisitions & Mergers
    • 4.2.2. New Test Type Launch
    • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
    • 4.2.4. Research and Development, Regional Expansion
•  
• Chapter 5. Global Oncology Biosimilar Market - Test Type Segment Analysis
  • 5.1. Global Oncology Biosimilar Market: Test Type overview
    • 5.1.1. Global Oncology Biosimilar Market revenue share, by Test Type, 2015 and 2023(USD Billion)
  • 5.2. Breast Cancer
    • 5.2.1. Global Breast Cancer market, 2015 - 2023(USD Billion)
  • 5.3. Colorectal Cancer
    • 5.3.1. Global Colorectal Cancer market, 2015 - 2023(USD Billion)
  • 5.4. Blood Cancer
    • 5.4.1. Global Blood Cancer market, 2015 - 2023(USD Billion)
  • 5.5. Neutropenia Cancer
    • 5.5.1. Global Neutropenia Cancer market, 2015 - 2023(USD Billion)
  • 5.6. Non-Small Cell Lung Cancer
    • 5.6.1. Global Non-Small Cell Lung Cancer market, 2015 - 2023(USD Billion)
  • 5.7. Others
    • 5.7.1. Global Others market, 2015 - 2023(USD Billion)
•  
• Chapter 6. Global Oncology Biosimilar Market - Drug Type Segment Analysis
  • 6.1. Global Oncology Biosimilar Market: Drug Type overview
    • 6.1.1. Global Oncology Biosimilar Market revenue share, by Drug Type, 2015 and 2023(USD Billion)
  • 6.2. mAb
    • 6.2.1. Global mAb market, 2015 - 2023(USD Billion)
  • 6.3. Immunomodulators
    • 6.3.1. Global Immunomodulators market, 2015 - 2023(USD Billion)
  • 6.4. Hematopoietic Agents
    • 6.4.1. Global Hematopoietic Agents market, 2015 - 2023(USD Billion)
  • 6.5. G-CSF
    • 6.5.1. Global G-CSF market, 2015 - 2023(USD Billion)
  • 6.6. Others
    • 6.6.1. Global Others market, 2015 - 2023(USD Billion)
•  
• Chapter 7. Global Oncology Biosimilar Market - Distribution Channel Segment Analysis
  • 7.1. Global Oncology Biosimilar Market: Distribution Channel overview
    • 7.1.1. Global Oncology Biosimilar Market revenue share, by Distribution Channel , 2014 and 2023(USD Billion)
  • 7.2. Retail Pharmacies
    • 7.2.1. Global Oncology Biosimilar Market for Retail Pharmacies, 2015 - 2023(USD Billion)
  • 7.3. Hospital Pharmacy
    • 7.3.1. Global Oncology Biosimilar Market for Hospital Pharmacy, 2015 - 2023(USD Billion)
  • 7.4. Online Pharmacy
    • 7.4.1. Global Oncology Biosimilar Market for Online Pharmacy, 2015 - 2023(USD Billion)
•  
• Chapter 8. Global Oncology Biosimilar Market - Regional Segment Analysis
  • 8.1. Global Oncology Biosimilar Market: Regional overview
    • 8.1.1. Global Oncology Biosimilar Market revenue share, by Region, 2015 and 2023
  • 8.2. North America
    • 8.2.1. North America Oncology Biosimilar Market revenue, by Test Type, 2015 - 2023(USD Billion)
    • 8.2.2. North America Oncology Biosimilar Market revenue, by Drug Type, 2015 - 2023(USD Billion)
    • 8.2.3. North America Oncology Biosimilar Market revenue, by Distribution Channel , 2015 - 2023(USD Billion)
    • 8.2.4. North America Oncology Biosimilar Market revenue, by Region, 2015 - 2023(USD Billion)
    • 8.2.5. U.S.
      • 8.2.5.1. U.S. Oncology Biosimilar Market revenue, by Test Type, 2015 - 2023(USD Billion)
      • 8.2.5.2. U.S. Oncology Biosimilar Market revenue, by Drug Type, 2015 - 2023(USD Billion)
      • 8.2.5.3. U.S. Oncology Biosimilar Market revenue, by Distribution Channel , 2015 - 2023(USD Billion)
      • 8.2.5.4. U.S. Oncology Biosimilar Market revenue, by Region, 2015 - 2023(USD Billion)
    • 8.2.6. Rest of North America
      • 8.2.6.1. Rest of North America Oncology Biosimilar Market revenue, by Test Type, 2015 - 2023(USD Billion)
      • 8.2.6.2. Rest of North America Oncology Biosimilar Market revenue, by Drug Type, 2015 - 2023(USD Billion)
      • 8.2.6.3. Rest of North America Oncology Biosimilar Market revenue, by Distribution Channel , 2015 - 2023(USD Billion)
      • 8.2.6.4. Rest of North America Oncology Biosimilar Market revenue, by Region, 2015 - 2023(USD Billion)
  • 8.3. Europe
    • 8.3.1. Europe Oncology Biosimilar Market revenue, by Test Type, 2015 - 2023(USD Billion)
    • 8.3.2. Europe Oncology Biosimilar Market revenue, by Drug Type, 2015 - 2023(USD Billion)
    • 8.3.3. Europe Oncology Biosimilar Market revenue, by Distribution Channel , 2015 - 2023(USD Billion)
    • 8.3.4. Europe Oncology Biosimilar Market revenue, by Region, 2015 - 2023(USD Billion)
    • 8.3.5. Germany
      • 8.3.5.1. Germany Oncology Biosimilar Market revenue, by Test Type, 2015 - 2023(USD Billion)
      • 8.3.5.2. Germany Oncology Biosimilar Market revenue, by Drug Type, 2015 - 2023(USD Billion)
      • 8.3.5.3. Germany Oncology Biosimilar Market revenue, by Distribution Channel , 2015 - 2023(USD Billion)
      • 8.3.5.4. Germany Oncology Biosimilar Market revenue, by Region, 2015 - 2023(USD Billion)
    • 8.3.6. U.K.
      • 8.3.6.1. U.K. Oncology Biosimilar Market revenue, by Test Type, 2015 - 2023(USD Billion)
      • 8.3.6.2. U.K. Oncology Biosimilar Market revenue, by Drug Type, 2015 - 2023(USD Billion)
      • 8.3.6.3. U.K. Oncology Biosimilar Market revenue, by Distribution Channel , 2015 - 2023(USD Billion)
      • 8.3.6.4. U.K. Oncology Biosimilar Market revenue, by Region, 2015 - 2023(USD Billion)
    • 8.3.7. France
      • 8.3.7.1. France Oncology Biosimilar Market revenue, by Test Type, 2015 - 2023(USD Billion)
      • 8.3.7.2. France Oncology Biosimilar Market revenue, by Drug Type, 2015 - 2023(USD Billion)
      • 8.3.7.3. France Oncology Biosimilar Market revenue, by Distribution Channel , 2015 - 2023(USD Billion)
      • 8.3.7.4. France Oncology Biosimilar Market revenue, by Region, 2015 - 2023(USD Billion)
    • 8.3.8. Rest of Europe
      • 8.3.8.1. Rest of Europe Oncology Biosimilar Market revenue, by Test Type, 2015 - 2023(USD Billion)
      • 8.3.8.2. Rest of Europe Oncology Biosimilar Market revenue, by Drug Type, 2015 - 2023(USD Billion)
      • 8.3.8.3. Rest of Europe Oncology Biosimilar Market revenue, by Distribution Channel , 2015 - 2023(USD Billion)
      • 8.3.8.4. Rest of Europe Oncology Biosimilar Market revenue, by Region, 2015 - 2023(USD Billion)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Oncology Biosimilar Market revenue, by Test Type, 2015 - 2023(USD Billion)
    • 8.4.2. Asia Pacific Oncology Biosimilar Market revenue, by Drug Type, 2015 - 2023(USD Billion)
    • 8.4.3. Asia Pacific Oncology Biosimilar Market revenue, by Distribution Channel , 2015 - 2023(USD Billion)
    • 8.4.4. Asia Pacific Oncology Biosimilar Market revenue, by Region, 2015 - 2023(USD Billion)
    • 8.4.5. China
      • 8.4.5.1. China Oncology Biosimilar Market revenue, by Test Type, 2015 - 2023(USD Billion)
      • 8.4.5.2. China Oncology Biosimilar Market revenue, by Drug Type, 2015 - 2023(USD Billion)
      • 8.4.5.3. China Oncology Biosimilar Market revenue, by Distribution Channel , 2015 - 2023(USD Billion)
      • 8.4.5.4. China Oncology Biosimilar Market revenue, by Region, 2015 - 2023(USD Billion)
    • 8.4.6. Japan
      • 8.4.6.1. Japan Oncology Biosimilar Market revenue, by Test Type, 2015 - 2023(USD Billion)
      • 8.4.6.2. Japan Oncology Biosimilar Market revenue, by Drug Type, 2015 - 2023(USD Billion)
      • 8.4.6.3. Japan Oncology Biosimilar Market revenue, by Distribution Channel , 2015 - 2023(USD Billion)
      • 8.4.6.4. Japan Oncology Biosimilar Market revenue, by region, 2015 - 2023(USD Billion)
    • 8.4.7. India
      • 8.4.7.1. India Oncology Biosimilar Market revenue, by Test Type, 2015 - 2023(USD Billion)
      • 8.4.7.2. India Oncology Biosimilar Market revenue, by Drug Type, 2015 - 2023(USD Billion)
      • 8.4.7.3. India Oncology Biosimilar Market revenue, by Distribution Channel , 2015 - 2023(USD Billion)
      • 8.4.7.4. India Oncology Biosimilar Market revenue, by region, 2015 - 2023(USD Billion)
    • 8.4.8. Rest of Asia Pacific
      • 8.4.8.1. Rest of Asia Pacific Oncology Biosimilar Market revenue, by Test Type, 2015 - 2023(USD Billion)
      • 8.4.8.2. Rest of Asia Pacific Oncology Biosimilar Market revenue, by Drug Type, 2015 - 2023(USD Billion)
      • 8.4.8.3. Rest of Asia Pacific Oncology Biosimilar Market revenue, by Distribution Channel , 2015 - 2023(USD Billion)
      • 8.4.8.4. Rest of Asia Pacific Oncology Biosimilar Market revenue, by region, 2015 - 2023(USD Billion)
  • 8.5. Latin America
    • 8.5.1. Latin America Oncology Biosimilar Market revenue, by Test Type, 2015 - 2023(USD Billion)
    • 8.5.2. Latin America Oncology Biosimilar Market revenue, by Drug Type, 2015 - 2023(USD Billion)
    • 8.5.3. Latin America Oncology Biosimilar Market revenue, by Distribution Channel , 2015 - 2023(USD Billion)
    • 8.5.4. Latin America Oncology Biosimilar Market revenue, by Region, 2015 - 2023(USD Billion)
    • 8.5.5. Brazil
      • 8.5.5.1. Brazil Oncology Biosimilar Market revenue, by Test Type, 2015 - 2023(USD Billion)
      • 8.5.5.2. Brazil Oncology Biosimilar Market revenue, by Drug Type, 2015 - 2023(USD Billion)
      • 8.5.5.3. Brazil Oncology Biosimilar Market revenue, by Distribution Channel , 2015 - 2023(USD Billion)
      • 8.5.5.4. Brazil Oncology Biosimilar Market revenue, by Region, 2015 - 2023(USD Billion)
    • 8.5.6. Rest of Latin America
      • 8.5.6.1. Rest of Latin America Oncology Biosimilar Market revenue, by Test Type, 2015 - 2023(USD Billion)
      • 8.5.6.2. Rest of Latin America Oncology Biosimilar Market revenue, by Drug Type, 2015 - 2023(USD Billion)
      • 8.5.6.3. Rest of Latin America Oncology Biosimilar Market revenue, by Distribution Channel , 2015 - 2023(USD Billion)
      • 8.5.6.4. Rest of Latin America Oncology Biosimilar Market revenue, by Region, 2015 - 2023(USD Billion)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa Oncology Biosimilar Market revenue, by Test Type, 2015 - 2023(USD Billion)
    • 8.6.2. Middle East and Africa Oncology Biosimilar Market revenue, by Drug Type, 2015 - 2023(USD Billion)
    • 8.6.3. Middle East and Africa Oncology Biosimilar Market revenue, by Distribution Channel , 2015 - 2023(USD Billion)
    • 8.6.4. Middle East and Africa Oncology Biosimilar Market revenue, by Region, 2015 - 2023(USD Billion)
•  
• Chapter 9. Company Profile
  • 9.1. Teva Pharmaceutical Industries Ltd.
    • 9.1.1. Overview
    • 9.1.2. Financials
    • 9.1.3. Therapy portfolio
    • 9.1.4. Business strategy
    • 9.1.5. Recent developments
  • 9.2. Biocon
    • 9.2.1. Overview
    • 9.2.2. Financials
    • 9.2.3. Therapy portfolio
    • 9.2.4. Business strategy
    • 9.2.5. Recent developments
  • 9.3. STADA Arzneimittel AG
    • 9.3.1. Overview
    • 9.3.2. Financials
    • 9.3.3. Therapy portfolio
    • 9.3.4. Business strategy
    • 9.3.5. Recent developments
  • 9.4. Sandoz International GmbH
    • 9.4.1. Overview
    • 9.4.2. Financials
    • 9.4.3. Therapy portfolio
    • 9.4.4. Business strategy
    • 9.4.5. Recent developments
  • 9.5. Intas Pharmaceuticals Ltd.
    • 9.5.1. Overview
    • 9.5.2. Financials
    • 9.5.3. Therapy portfolio
    • 9.5.4. Business strategy
    • 9.5.5. Recent developments
  • 9.6. Celltrion Inc.
    • 9.6.1. Overview
    • 9.6.2. Financials
    • 9.6.3. Therapy portfolio
    • 9.6.4. Business strategy
    • 9.6.5. Recent developments

Methodology

Free Analysis

Biosimilar is a biological medical product which is an identical copy of the original product manufactured by the companies. Biosimilar is the approved version of innovative products and can only be manufactured after the patent expiry of the original product. Oncology biosimilar is different as compared to the biologics in terms of complexity and manufacturing process. The biosimilar is much cheaper as compared to branded and approved products which are available in the market. There are several biologics available in the market for oncology which is on its way of patent expiry. Patent expiry of branded biologics will increase the biosimilar market. Biosimilar can be used for the treatment of various types of cancer such as lung cancer, kidney cancer, and others which are expected to open the gates of opportunities for the biosimilar market in the near future.

One of the major factors driving the oncology biosimilar market is the increasing demand for affordable therapies due to the constant increase in cancer patients worldwide. Various pharmaceutical companies are involved in the development of oncology biosimilar and generic medicines for the treatment of cancer at all stages and early detection of cancer. Due to the high demand for the cancer treatment, there is a rapid rate of approval observed in past few years which are expected to drive the oncology biosimilar market. The first biosimilar was approved in 2006 in Europe, and in the U.S. first biosimilar was approved in 2015 after the approval of first biosimilar FDA has approved five biosimilars in 2017. There is a number of applications pending for the approval of oncology biosimilar and their approval in future are expected to support the growth of oncology biosimilar market.

Based on cancer type, oncology biosimilar market is segmented into breast cancer, colorectal cancer, blood cancer, neutropenia cancer, non-small cell lung cancer and others. On the basis of drug type, oncology biosimilar market is segmented into mAb, immunomodulators, hematopoietic agents, G-CSF, and others. G-CSF segment is expected to grow at the fastest rate during the forecast period. Based on the distribution channel, oncology biosimilar market is segmented into retail pharmacies, hospital pharmacy, and online pharmacy. Hospital pharmacy segment is expected to grow at the fastest rate during the forecast period.

North America is expected to remain the dominant region over the forecast period which is closely followed by Europe. Due to the increased patent expiration and FDA approval of the new drugs the oncology biosimilar market is anticipated to grow rapidly over the forecast period. The Asia Pacific is expected to experience significant growth over the forecast period due to the increase in strategic collaboration in this region. Latin America and the Middle East & Africa are expected to experience a considerable growth over the forecast period. All the above-mentioned factors are responsible for the growth of oncology biosimilar market over the forecast period.

Some of the key players of the oncology biosimilar market include Teva Pharmaceutical Industries Ltd., Biocon, STADA Arzneimittel AG, Sandoz International GmbH, Intas Pharmaceuticals Ltd., Celltrion Inc., Pfizer Inc., Apotex Inc., Dr. Reddy’s Laboratories Ltd., and BIOCAD, among others.